The strategic review process (sale/merger) is the key catalyst. Monitor for any definitive agreement, additional financing, or FDA meeting outcome. Cash runway into Q1 2027 creates urgency for a transaction.
Drug in focus
LGVN drug pipeline →laromestrocel
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Not stated
- Next catalyst
- None dated
What to watchThe next near-term event is the AHA 2026 Scientific Sessions podium presentation of the ELPIS II secondary endpoint data (date TBD). A positive reception could provide a short-term bounce, but the primary endpoint failure already limits the HLHS regulatory path. The bigger binary is the outcome of the strategic alternatives review, a sale or partnership could unlock value, while failure to find a deal could force a dilutive financing or a wind-down. Watch for 8-K filings for any 8-K regarding a potential sale, financing or Nasdaq compliance notice.
Price Chart
Executive Summary
Longeveron reported Q3 2026 revenue of $0.1M, down 16% YoY, and a net loss of $6.1M (improved from $7.2M). The ELPIS II Phase 2b trial in HLHS missed its primary endpoint; the company has requested an FDA meeting and initiated a strategic review process with Lucid Capital Markets to explore a sale or merger. Cash stands at $7.2M, expected to fund operations into Q1 2027.
Key Financial Metrics
Key Facts
- ELPIS II Phase 2b trial did not meet primary efficacy endpoint of change in RVEF at Month 12
- Revenue for Q3 2026 was $0.1 million, down 16% YoY from $0.1 million
- Net loss for Q3 2026 was $6.1 million, improved from $7.2 million in Q3 2025
- Cash and cash equivalents of $7.2 million as of September 30, 2026
- Company initiated a review of strategic alternatives including a potential sale or merger
- Lucid Capital Markets retained as financial advisor
- Cash runway expected into Q1 2027 based on current budget and conservation measures
- Company has requested a meeting with FDA to discuss ELPIS II results and next steps for HLHS program
- 1-for-10 reverse stock split implemented effective August 26, 2026
Financial Impact
Revenue $0.1M (down 16% YoY); net loss $6.1M; cash $7.2M
Risk Factors
- ELPIS II primary endpoint miss significantly reduces HLHS program value
- Cash runway only into Q1 2027; substantial doubt about going concern without financing or deal
- Strategic review may not result in any transaction or favorable terms
- Nasdaq continued listing risk given low stock price and market cap
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-119052 |
| Document: ea0311944-8k_longeveron.htm | 0001213900-26-119052 |
| Document: 0001213900-26-119052-index-headers.html | 0001213900-26-119052 |
| Document: 0001213900-26-119052-index.html | 0001213900-26-119052 |
| Document: 0001213900-26-119052.txt | 0001213900-26-119052 |
| 8-K Data (Synthetic) | 0001213900-26-119052 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 Viewing No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers